Chief Medical Officer · OCULAR THERAPEUTIX, INC (OCUL)

Rabia Ozden

A named executive officer of OCULAR THERAPEUTIX in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,480,155

Salary $462,800Stock awards $215,557Bonus $221,797

FY2022: $1,487,791

2nd of 3 named executive officers at Ocular Therapeutix by FY2023 total.

3 named officers on file for OCULAR THERAPEUTIX, FY2023

Rabia Ozden’s pay file — $29

  • 2 fiscal years of pay, line by line
  • OCUL’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how OCULAR THERAPEUTIX’s whole pay program stands against its peers

  • OCULAR THERAPEUTIX’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on OCUL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2024 (DEF 14A).

Free

Get Rabia Ozden’s full pay file as a PDF — free

More than this page: up to 10 years of Rabia’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Rabia Ozden compensation by year

OCULAR THERAPEUTIX Summary Compensation Table · all 2 fiscal years held
In US dollars, as OCULAR THERAPEUTIX reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$427,898$462,800
Bonus$190,238$221,797
Stock awards$267,348$215,557
Option awards$599,057$577,249
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$3,250$2,752
Total$1,487,791$1,480,155

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: OCULAR THERAPEUTIX, INC DEF 14A filed April 29, 2024, accession 0001558370-24-006110, and prior-year filings. Open the filing on EDGAR.

How this page was built: the OCULAR THERAPEUTIX, INC filed document, accession 0001558370-24-006110. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2024.

$1.5M
$1.5M
FY22
FY23
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU55,556$247,780—
RSU30,371$135,455—
RSU4,445$19,825—
Option5,833—$18.70
Option74,029—$5.27
Option4,333—$4.30
Option27,083—$3.88
Option20,834—$18.70
Option12,917—$4.09

Per the Outstanding Equity Awards at Fiscal Year-End table in OCULAR THERAPEUTIX, INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

OCULAR THERAPEUTIX’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Antony MattessichFormer President and Chief Executive Officer$3,276,712
Rabia Ozden · this pageChief Medical Officer$1,480,155
Donald NotmanChief Financial Officer$1,343,494

The full OCULAR THERAPEUTIX compensation record

free company brief

This page is one person within OCULAR THERAPEUTIX's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the OCULAR THERAPEUTIX proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are OCULAR THERAPEUTIX's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Rabia Ozden's compensation dossier · One-time report. No refunds.